BIOCYTOGEN
25.3.2024 14:13:25 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
Eclipse Signs Partnership Agreement With BNP Paribas to Power the Next Stage of Growth11.2.2026 00:05:00 CET | Press release
The agreement includes a strategic equity investment in Eclipse by BNP Paribas Eclipse, a leading battery storage, development, and energy trading company, and BNP Paribas, one of the largest banks in the Eurozone, today announced a strategic partnership to accelerate the deployment of Battery Energy Storage Systems (BESS) and strengthen Europe's energy resilience. This partnership includes a strategic equity investment in Eclipse by BNP Paribas. Through its proprietary algo trading software, Flowstream, Eclipse optimizes battery energy storage assets in real-time for its own and third-party assets. As an integrated BESS player, Eclipse develops, owns, and operates industrial-scale energy assets. The company currently has a pipeline of 16 projects in France and Belgium, representing a total capacity of 850 MW. The partnership with BNP Paribas provides asset owners with tailored financing solutions for BESS projects, as well as hedging instruments to manage merchant risk and reduce asse
World Governments Summit 2027 Date Announced, Following Largest-Ever Global Participation10.2.2026 22:06:00 CET | Press release
Largest edition in the summit’s history convened 6,250+ global leaders, policymakers, and experts from 150+ countriesWorld leaders, including presidents from Switzerland, Sierra Leone, and beyond, lead strategic dialogues Under the leadership of UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the World Governments Summit concluded in Dubai with its largest-ever participation, featuring more than 6,250 attendees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210283291/en/ World Governments Summit 2026 concludes in Dubai with record participation, bringing together more than 6,250 global leaders from over 150 countries to advance dialogue on governance, innovation, and sustainable development (Photo: AETOSWire) A Global Platform Convening Global Leaders Held in Dubai from 3 to 5 February, t
Palantir and Airbus Extend Strategic Collaboration10.2.2026 22:01:00 CET | Press release
Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform. The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges. This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-ed
Grand Prix ACF AutoTech 2026 Unveils Its Six Finalist Startups10.2.2026 19:31:00 CET | Press release
The jury of the Grand Prix ACF AutoTech 2026, which met on February 9 at the Automobile Club de France, has selected six finalist startups following several hours of deliberation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210456562/en/ Jury members The selected companies stand out for their technological ambition, economic viability and tangible impact on automotive cost reduction and industrial performance. Key themes this year include AI-assisted engineering design, strategic independence from critical materials, and advanced LiDAR optimization. Finalist startups include: Grand Prix ACF (Mature startups) - Altrove (Paris, France): Develops innovative alternatives to high-risk critical inorganic materials using a proprietary algorithmic approach and unique artificial intelligence, strengthening industrial resilience and technological sovereignty. - Cognitive Design Systems (Toulouse, France): Provides an AI-powered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom